Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2001, we proposed to restore this balance using judicious doses of antiangiogenic agents and suggested that this strategy would transiently give rise to tumour vessels with structural and functional phenotypes closer to those of the vessels of nonmalignant tissues — a state we referred to as ‘normalized’ (REF. 61)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“We also suggested that the use of other therapies during this ‘window of normalization’ (REF. 61) would result in better outcomes than if the same agents were given before or after this window.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“Traditional angiogenesis inhibitors mainly block VEGF signaling and prune rather than eradicate tumor vessels.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [78]
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“What mechanisms are responsible for this normalization? How can we exploit them? This knowledge will affect the treatment not only of cancer but also of other diseases characterized by abnormal vasculature—such as hemangiomas, arteriovenous malformations, diabetic retinopathy and macular degeneration—for which anti-an…”
BackgroundSelf-citationGenes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Self-citationLee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 733
Self-citationYuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Self-citationBaish, J. W., & Jain, R. K. (2000) · PubMed · Cited by 714
Self-citationThe next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Self-citation
Research works printed but not linked: 6
- Folkman, J. in Harrison's Textbook of Internal Medicine, 15th ed. (eds Braunwald, E. et al.) 517–530 (McGraw-Hill, New York, 2001).
- Kozin, S.V. et al. VEGF receptor-2 blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1α→HRE→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research 60, 6248–6252 (2000).
- Kadambi, A. et al. Vascular endothelial growth factor (VEGF)–C differentially affects tumor vascular function and leukocyte recruitment. Cancer Res. 61, 2404–2408 (2001).
- Lee, C.G. et al. Anti-VEGF treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
- Hansen-Algenstaedt, N. et al. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60, 4556–4560 (2000).
Cited by
Items 601–700 of 1,004
Zips, D., Eicheler, W., Geyer, P., Hessel, F., Dörfler, A., Thames, H. D., Haberey, M., & Baumann, M. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3379 · Cited by 57
Verreault, M., Strutt, D., Masin, D., Anantha, M., Yung, A., Kozlowski, P., Waterhouse, D., Bally, M. B., & Yapp, D. T. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-124 · Cited by 56
“In glioma [28,29,40], antiangiogenic therapies can stop the growth of tumor vessels, prune immature and inefficient tumor vessels and normalize surviving vasculature by increasing the fraction of pericyte-covered vessels, restoring the abnormally thick and irregular basement membrane and reducing the high vascular per…”
BackgroundResultInfluentialHe, T., Hao, Z., Lin, M., Xin, Z., Chen, Y., Ouyang, W., Yang, Q., Chen, X., Zhou, H., Zhang, W., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2093054 · Cited by 58
Jain, R., Narang, J., Sundgren, P. C., Hearshen, D., Saksena, S., Rock, J. P., Gutierrez, J. A., & Mikkelsen, T. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0139-3 · Cited by 56
Self-citationIncorporating contrast agent diffusion into the analysis of DCE‐MRI data
Pellerin, M., Yankeelov, T. E., & Lepage, M. (2007) · Magnetic Resonance in Medicine · doi:10.1002/mrm.21400 · Cited by 56
Zhang, R., Pan, D., Cai, X., Yang, X., Senpan, A., Allen, J. S., Lanza, G. M., & Wang, L. V. (2014) · Theranostics · doi:10.7150/thno.10014 · Cited by 60
Tortuous Microvessels Contribute to Wound Healing via Sprouting Angiogenesis
Chong, D. C., Yu, Z., Brighton, H. E., Bear, J. E., & Bautch, V. L. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309993 · Cited by 58
Off-tumor target—beneficial site for antiangiogenic cancer therapy?
Cao, Y. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.118 · Cited by 56
Cao, C., Albert, J. M., Geng, L., Ivy, P. S., Sandler, A. B., Johnson, D. H., & Lü, B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2414 · Cited by 59
Paz, K. (2005) · Frontiers in bioscience · doi:10.2741/1629 · Cited by 61
Yu, H., Teng, L., Meng, Q., Li, Y., Sun, X., Lu, J., Lee, R. J., & Teng, L. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.04.065 · Cited by 55
Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers
Benzekry, S., & Hahnfeldt, P. (2013) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2013.06.036 · Cited by 55
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives
Shang, B., Cao, Z., & Zhou, Q. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0176-8 · Cited by 57
Hoyt, K., Warram, J. M., Umphrey, H. R., Belt, L., Lockhart, M. E., Robbin, M. L., & Zinn, K. R. (2010) · Journal of Ultrasound in Medicine · doi:10.7863/jum.2010.29.4.577 · Cited by 55
Ozcelikkale, A., Ghosh, S., & Han, B. (2013) · Molecular Pharmaceutics · doi:10.1021/mp3005947 · Cited by 55
Nam, K., Eisenbrey, J. R., Stanczak, M., Sridharan, A. N., Berger, A. C., Avery, T. P., Palazzo, J., & Forsberg, F. (2017) · Radiology · doi:10.1148/radiol.2017161683 · Cited by 58
Jiang, L., Ding, Y., Xue, X., Zhou, S., Li, C., Zhang, X., & Jiang, X. (2018) · Nano Research · doi:10.1007/s12274-018-2123-8 · Cited by 56
Hillman, G. G., Singh‐Gupta, V., Zhang, H., Al‐Bashir, A. K., Katkuri, Y., Li, M., Yunker, C. K., Patel, A. D., Abrams, J., & Haacke, E. M. (2009) · Neoplasia · doi:10.1593/neo.09618 · Cited by 58
Endostatin Signaling and Regulation of Endothelial Cell–Matrix Interactions
Wickström, S. A., Alitalo, K. K., & Keski‐Oja, J. (2005) · Advances in cancer research · doi:10.1016/s0065-230x(05)94005-0 · Cited by 61
Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer
Maalouf, G. E., Tourneau, C. L., Batty, G. N., Faivre, S. J., & Raymond, É. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.10.002 · Cited by 57
A novel DDS strategy, “dual-targeting”, and its application for antineovascular therapy
Murase, Y., Asai, T., Katanasaka, Y., Sugiyama, T., Shimizu, K., Maeda, N., & Oku, N. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.06.008 · Cited by 55
The application and research progress of anti-angiogenesis therapy in tumor immunotherapy
Tu, J., Liang, H., Li, C., Huang, Y., Wang, Z., Chen, X., & Yuan, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1198972 · Cited by 56
Pan-cancer integrative analyses dissect the remodeling of endothelial cells in human cancers
Li, J., Wang, D., Tang, F., Ling, X., Zhang, W., & Zhang, Z. (2024) · National Science Review · doi:10.1093/nsr/nwae231 · Cited by 58
Reversibly Crosslinked Nanocarriers for on-demand Drug Delivery in Cancer Treatment
Shao, Y., Huang, W., Shi, C., Atkinson, S. T., & Luo, J. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.106 · Cited by 55
Targeted treatments in colorectal cancer: state of the art and future perspectives
Arnold, D., & Seufferlein, T. (2010) · Gut · doi:10.1136/gut.2009.196006 · Cited by 67
Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy
Huang, L., Perrault, C., Coelho-Martins, J., Hu, C., Dulong, C., Varna, M., Liu, J., Jin, J., Soria, C., Cazin, L., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-49 · Cited by 58
New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma
Mossenta, M., Busato, D., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Cancers · doi:10.3390/cancers11081086 · Cited by 56
Wang, J., Zhang, H., Xiao, X., Liang, D., Liang, X., Mi, L., Wang, J., & Liu, J. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.03.001 · Cited by 56
Angiogenesis and its role in colorectal tumor and metastasis formation
Ellis, L. M. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.11.028 · Cited by 56
Drappatz, J., Wong, E. T., Schiff, D., Kesari, S., Batchelor, T. T., Doherty, L. M., LaFrankie, D. C., Ramakrishna, N. R., Weiss, S. E., Smith, S. T., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.03.046 · Cited by 54
Vascular Endothelial Growth Factor Pharmacogenetics: a New Perspective for Anti-Angiogenic Therapy
Pasqualetti, G., Danesi, R., Tacca, M. D., & Bocci, G. (2006) · Pharmacogenomics · doi:10.2217/14622416.8.1.49 · Cited by 64
Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma.
Pan, Q., Bao, L., Kleer, C. G., Brewer, G. J., & Merajver, S. D. (2003) · PubMed · Cited by 54
Clinical Applications of VEGF-Trap (Aflibercept) in Cancer Treatment
Teng, L., Jin, K., He, K., Zhang, J., Wang, H., & Cao, J. (2010) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(10)70097-6 · Cited by 53
Multistage Nanoparticles for Improved Delivery into Tumor Tissue
Stylianopoulos, T., Wong, C., Bawendi, M. G., Jain, R. K., & Fukumura, D. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-391860-4.00006-9 · Cited by 50
Self-citationValable, S., Petit, E., Roussel, S., Marteau, L., Toutain, J., Divoux, D., Sobrio, F., Delamare, J., Barré, L., & Bernaudin, M. (2011) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.01.010 · Cited by 55
Zhao, Y., Xue, C., Jiang, W., Zhao, H.-Y., Huang, Y., Feenstra, K., Resau, J. H., Qian, C.-N., & Zhang, L. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823085f4 · Cited by 53
Schuster, C., Eikesdal, H. P., Puntervoll, H. E., Geisler, J., Geisler, S. B., Heinrich, D., Molven, A., Lønning, P. E., Akslen, L. A., & Straume, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038364 · Cited by 53
Hansen, T. F., Sørensen, F. B., Lindebjerg, J., & Jakobsen, A. K. M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-83 · Cited by 57
Antiangiogenic therapy: Markers of response, “normalization” and resistance
Alaoui‐Lasmaili, K. E., & Faivre‐Fiorina, B. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.001 · Cited by 55
Kareva, I. (2019) · Stem Cells · doi:10.1002/stem.3051 · Cited by 48
Transcriptional regulation of human angiopoietin-2 by transcription factor Ets-1
Hasegawa, Y., Abé, M., Yamazaki, T., Niizeki, O., Shiiba, K., Sasaki, I., & Sato, Y. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.02.019 · Cited by 59
Systemic cancer therapy: Evolution over the last 60 years
Dy, G. K., & Adjei, A. A. (2008) · Cancer · doi:10.1002/cncr.23651 · Cited by 65
Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology
LoRusso, P. M., & Eder, J. P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.7.1013 · Cited by 56
Role of angiogenesis in chronic lymphocytic leukemia
Letilović, T., Vrḫovac, R., Verstovšek, S., Jaksic, B. S., & Ferrajoli, A. (2006) · Cancer · doi:10.1002/cncr.22086 · Cited by 53
Tabernero, J., Taieb, J., Prager, G. W., Ciardiello, F., Fakih, M., Leger, C., Fougeray, R., Amellal, N., & van Cutsem, E. (2021) · Future Oncology · doi:10.2217/fon-2020-1238 · Cited by 46
Simitian, G. S., Virumbrales-Muñoz, M., Sánchez‐de‐Diego, C., Beebe, D. J., & Kosoff, D. (2022) · Lab on a Chip · doi:10.1039/d2lc00352j · Cited by 56
Current views on mechanisms of the FLASH effect in cancer radiotherapy
Ma, Y., Zhang, W., Zhao, Z.-M., Lv, J., Chen, J., Yan, X., Lin, X., Zhang, J., Wang, B., Gao, S., et al. (2024) · National Science Review · doi:10.1093/nsr/nwae350 · Cited by 55
Abuqayyas, L., & Balthasar, J. P. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9279-8 · Cited by 51
Idbaïh, A., Ducray, F., del Río, M. A. S., Hoang‐Xuan, K., & Delattre, J. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0056 · Cited by 54
Kim, S. H., Cho, Y., Kim, H., Oh, J. S., Ahn, E., Ko, H., Hwang, B. J., Lee, S.-J., Cho, Y., Kim, Y. K., et al. (2012) · Blood · doi:10.1182/blood-2012-05-428243 · Cited by 54
EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer
Mondal, G., Kumar, V., Shukla, S. K., Singh, P. K., & Mahato, R. I. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b01419 · Cited by 56
Spatial Metrics of Tumour Vascular Organisation Predict Radiation Efficacy in a Computational Model
Scott, J. G., Fletcher, A. G., Anderson, A. R. A., & Maini, P. K. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004712 · Cited by 55
Heterogeneity of colon cancer: from bench to bedside
Merlano, M. C., Granetto, C., Fea, E., Ricci, V., & Garrone, O. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000218 · Cited by 58
Chen, L., Chang, C.-H., Yu, C., Chang, Y., Wu, Y.-H., Lee, W., Yeh, C., Lee, T., & Ting, G. (2008) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.09.005 · Cited by 52
Molecular-targeted therapies: Lessons from years of clinical development
Rosa, D. D., Ismael, G., Lago, L. D., & Awada, A. H. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.07.019 · Cited by 54
Rademaker-Lakhai, J. M., Beerepoot, L. V., Mehra, N., Radema, S. A., van Maanen, R. J., Vermaat, J. S. P., Witteveen, E. O., Visseren‐Grul, C., Musib, L. C., Enas, N. H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2912 · Cited by 56
Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer
Liu, W., Jung, Y. D., Ahmad, S. A., McCarty, M. F., Stoeltzing, O., Reinmuth, N., Fan, F., & Ellis, L. M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601723 · Cited by 52
Overcoming physical stromal barriers to cancer immunotherapy
Chung, S. W., Xie, Y., & Suk, J. S. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01036-y · Cited by 54
Falk, A. T., Barrière, J., François, É., & Follana, P. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.01.012 · Cited by 57
Effectiveness and Safety of Bevacizumab for Unresectable Non-Small-Cell Lung Cancer: A Meta-Analysis
Yang, K., Wang, Y., Chen, X., & Chen, H. (2010) · Clinical Drug Investigation · doi:10.2165/11532260-000000000-00000 · Cited by 56
Mutually Supportive Mechanisms of Inflammation and Vascular Remodeling
Whiteford, J. R., Rossi, G. D., & Woodfin, A. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.001 · Cited by 55
Takara, K., Eino, D., Ando, K., Yasuda, D., Naito, H., Tsukada, Y., Iba, T., Wakabayashi, T., Muramatsu, F., Kidoya, H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.080 · Cited by 51
Modelling the transport of fluid through heterogeneous, whole tumours in silico
Sweeney, P. W., d’Esposito, A., Walker‐Samuel, S., & Shipley, R. J. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006751 · Cited by 54
Dosch, A. R., Dai, X., Reyzer, M. L., Mehra, S., Srinivasan, S., Willobee, B. A., Kwon, D., Kashikar, N., Caprioli, R. M., Merchant, N. B., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0741 · Cited by 53
Rybak, S. M., Sanovich, E., Hollingshead, M. G., Borgel, S. D., Newton, D. L., Melillo, G., Kong, D., Kaur, G., & Sausville, E. A. (2003) · PubMed · Cited by 56
Applications and Perspectives of Boron-Enriched Nanocomposites in Cancer Therapy
Zhu, Y., & Hosmane, N. S. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.47 · Cited by 51
Essock-Burns, E., Lupo, J., Cha, S., Polley, M.-Y., Butowski, N. A., Chang, S., & Nelson, S. J. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq143 · Cited by 51
Practical consideration for 3T imaging
Lin, W., An, H., Chen, Y., Nicholas, P., Zhai, G., Gerig, G., Gilmore, J. H., & Bullitt, E. (2003) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/s1064-9689(03)00068-0 · Cited by 54
Tumor Hypoxia: Chicken, Egg, or a Piece of the Farm?
Coleman, C. N., Mitchell, J. B., & Camphausen, K. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.610 · Cited by 51
Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution.
Huang, D., Lan, H., Liu, F., Wang, S., Chen, X., Jin, K., & Mou, X. (2015) · Europe PMC (PubMed Central) · Cited by 59
Circulating and imaging markers for angiogenesis
Pathak, A. P., Hochfeld, W. E., Goodman, S. L., & Pepper, M. S. (2008) · Angiogenesis · doi:10.1007/s10456-008-9119-z · Cited by 50
Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer
Koukourakis, G. V., & Sotiropoulou‐Lontou, A. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0720-z · Cited by 50
Clinical biomarkers of angiogenesis inhibition
Brown, A. P., Citrin, D. E., & Camphausen, K. A. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9143-x · Cited by 50
Chang, D.-K., Li, P., Lu, R., Jane, W., & Wu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083239 · Cited by 52
Behzadi, S., Gallei, M., Elbert, J., Appold, M., Glaßer, G., Landfester, K., & Crespy, D. (2016) · Polymer Chemistry · doi:10.1039/c6py00344c · Cited by 53
Fernández-Martos, C., Pericay, C., Losa, F., García‐Carbonero, R., Layos, L., Rodríguez-Salas, N., Martín-Richard, M., Alonso-Orduña, V., Vera, R., Gallego-Plazas, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2294 · Cited by 51
Self-citationHIF-1 stabilization exerts anticancer effects in breast cancer cells in vitro and in vivo
Kachamakova‐Trojanowska, N., Podkalicka, P., Bogacz, T., Barwacz, S. A., Józkowicz, A., Dulak, J., & Łoboda, A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113922 · Cited by 51
Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors
Li, L., Chen, X. S., Yu, J., & Yuan, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837952 · Cited by 56
Winslow, T. B., Eranki, A., Ullas, S., Singh, A. K., Repasky, E. A., & Sen, A. (2015) · International Journal of Hyperthermia · doi:10.3109/02656736.2015.1037800 · Cited by 50
Wen, Q., Meng, M., Yang, B. Y., Tu, L., Li, J., Zhou, L., Xu, Y., & Lü, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01193.x · Cited by 50
Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope
Medina, M. Á., Muñoz‐Chápuli, R., & Quesada, A. R. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00056.x · Cited by 55
Regulation of tumor angiogenesis by the local environment
Hall, K. L., & Ran, S. (2009) · Frontiers in bioscience · doi:10.2741/3615 · Cited by 57
Rumjahn, S. M., Javed, M., Wong, N., Law, W. E., & Buxton, I. L. O. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604019 · Cited by 50
Selective Alpha-Particle Mediated Depletion of Tumor Vasculature with Vascular Normalization
Jaggi, J. S., Henke, E., Seshan, S. V., Kappel, B. J., Chattopadhyay, D., May, C., McDevitt, M. R., Nolan, D., Mittal, V., Benezra, R., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000267 · Cited by 57
Moen, I., Tronstad, K. J., Kolmannskog, O., Salvesen, G. S., Reed, R. K., & Stuhr, L. E. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-446 · Cited by 49
“Tumor vessels are hyperpermeable due to up-regulation of vascular mediators such as nitric oxide, bradykinin as well as anatomic defects like large gap junctions between adjacent cells and lack of pericytes [36,39].”
BackgroundSystemic therapy of hepatocellular carcinoma: Current status and future perspectives
Germano, D., & Daniele, B. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i12.3087 · Cited by 51
A novel imaging‐based high‐throughput screening approach to anti‐angiogenic drug discovery
Evensen, L., Micklem, D., Link, W., & Lorens, J. B. (2009) · Cytometry Part A · doi:10.1002/cyto.a.20808 · Cited by 50
Faes, S., Santoro, T., Demartines, N., & Dormond, O. (2017) · Cancers · doi:10.3390/cancers9110152 · Cited by 50
PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer
Zhang, X., Wang, K., Feng, X., Wang, J., Chu, Y., Jia, C., He, Q., & Chen, C. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04352-w · Cited by 49
Baker, J. H. E., Lam, J., Kyle, A. H., Sy, J., Oliver, T., Co, S. J., Dragowska, W. H., Ramsay, E., Anantha, M., Ruth, T. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0736 · Cited by 51
Tortuosity and other vessel attributes for arterioles and venules of the human cerebral cortex
Lorthois, S., Lauwers, F., & Cassot, F. (2013) · Microvascular Research · doi:10.1016/j.mvr.2013.11.003 · Cited by 61
Bao, X., Shen, N., Lou, Y., Yu, H., Wang, Y., Liu, L., Tang, Z., & Chen, X. (2021) · Theranostics · doi:10.7150/thno.58164 · Cited by 48
Reprogramming endothelial cells to empower cancer immunotherapy
Cleveland, A. H., & Fan, Y. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.11.002 · Cited by 54
Class 3 semaphorins: physiological vascular normalizing agents for anti‐cancer therapy
Serini, G., Bussolino, F., Maione, F., & Giraudo, E. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12017 · Cited by 50
Qayum, N., Im, J. H., Stratford, M. R. L., Bernhard, E. J., McKenna, W. G., & Muschel, R. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1413 · Cited by 55
Sun, C., Jain, R. K., & Munn, L. L. (2007) · Annals of Biomedical Engineering · doi:10.1007/s10439-007-9377-8 · Cited by 51
Self-citationAngiogenesis in human cancer: implications in cancer therapy
Bamias, A., & Dimopoulos, M. A. (2003) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2003.10.003 · Cited by 56
Contrast-Enhanced Computed Tomography and Ultrasound for the Evaluation of Tumor Blood Flow
Broumas, A. R., Pollard, R. E., Bloch, S. H., Wisner, E. R., Griffey, S. M., & Ferrara, K. W. (2005) · Investigative Radiology · doi:10.1097/01.rli.0000152833.35744.7f · Cited by 48
Chemotherapy of vascularised tumours: Role of vessel density and the effect of vascular “pruning”
d’Onofrio, A., & Gandolfi, A. (2010) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2010.01.023 · Cited by 47
Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity
Yang, Y., Gorzelanny, C., Bauer, A. T., Halter, N., Komljenovic, D., Bäuerle, T., Borsig, L., Roblek, M., & Schneider, S. W. (2015) · Oncogene · doi:10.1038/onc.2015.40 · Cited by 47
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Medicine
- Published
- 2001-09
- Volume
- 7
- Issue
- 9
- Pages
- 987-989
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1603230122
- Cited by
- 2,184
- References
- 26
- Citations by year
- 2026: 58 · 2025: 65 · 2024: 61 · 2023: 88 · 2022: 97 · 2021: 91 · 2020: 93 · 2019: 91 · 2018: 69 · 2017: 94 · 2016: 82 · 2015: 106 · 2014: 94 · 2013: 101 · 2012: 124
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, tumor vasculature normalization, solid tumors, cancer prevention, combination therapy, drug delivery to tumors, tumor vasculature
- MeSH terms
- Blood Vessels, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.